Altimmune (NASDAQ: ALT) has announced that a late-breaking abstract featuring results from the RECLAIM Phase 2 trial evaluating pemvidutide in adults with moderate-to-severe alcohol use disorder (AUD) has been accepted as an oral presentation at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting 2026, taking place November 5-9, 2026, in Denver, Colorado.
The abstract is titled “Efficacy and Safety of Pemvidutide in the Treatment of Adults with Alcohol Use Disorder: Results from RECLAIM, a 24-Week Phase 2 Randomized Double-Blind Placebo-Controlled Trial.”
According to Altimmune, this first presentation at an international scientific conference will feature key results from the randomized, double-blind, placebo-controlled trial evaluating once-weekly pemvidutide 2.4 mg versus placebo over 24 weeks. In topline results announced in July 2026, pemvidutide achieved the trial’s primary endpoint of a statistically significant reduction in heavy drinking days (HDD) per week compared with placebo, and met key secondary endpoints validated by the FDA as registrational endpoints, including reduction in World Health Organization Risk Drinking Levels and zero HDD, with a generally favorable tolerability profile.
